Idorsia will host a live investor Q&A webcast and conference call following the publication of the OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment landscape for difficult-to-control hypertension. Date: Monday, September 8, 2025 Time: 16:00 CEST / 15:00 BST / 10:00 EDT The call will start with a short presentation by senior management followed by a Q&A session. Live Webcast (audio + slides):The ...